TY - JOUR
T1 - Cytokines secreted by bone-metastatic breast cancer cells alter the expression pattern of f-actin and reduce focal adhesion plaques in osteoblasts through PI3K
AU - Mercer, Robyn R.
AU - Mastro, Andrea M.
N1 - Funding Information:
We would like to thank Dr. Carol Gay and Dr. Danny Welch for their helpful discussion, and Elaine Kunze and Susan Magargee for help with microscopy. We thank Karen Bussard for her help with some of the cytokine experiments. This work was supported by Biotechnology Grant, Life Sciences Consortium, Pennsylvania State University and the PA Tobacco Settlement Fund. R.R.M. is supported by a pre-doctoral grant from the US Army Medical Research Materiel Command Under DAMD 17-02-1-0358.
PY - 2005/11/1
Y1 - 2005/11/1
N2 - Breast cancer frequently metastasizes to bone, resulting in osteolytic lesions. These lesions, formed by activated osteoclasts, cause pain, an increased susceptibility to fractures, and hypercalcemia. It has been shown that breast cancer cells communicate with osteoblasts and subsequently stimulate osteoclast activity; however, little research has focused on understanding the interaction between breast cancer cells and osteoblasts. We recently reported that conditioned medium from MDA-MB-231 breast cancer cells inhibited the differentiation of MC3T3-E1 osteoblasts through the secretion of transforming growth factor β (TGFβ). In addition, the breast cancer conditioned medium altered MC3T3-E1 morphology, the pattern of actin stress fibers, and reduced focal adhesion plaques. In the current study, we identified the mechanism used by MDA-MB-231 cells to cause these effects. When MC3T3-E1 osteoblasts were cultured with MDA-MB-231 conditioned medium preincubated with neutralizing antibodies to platelet derived growth factor (PDGF), insulin-like growth factorII (IGFII), and TGFβ, focal adhesion plaques and actin stress fiber formation were restored. These cytokines were further found to signal through PI3Kinase and Rac. In conclusion, TGFβ, PDGF, and IGFII might be good therapeutic targets for treating breast cancer-induced osteolytic lesions.
AB - Breast cancer frequently metastasizes to bone, resulting in osteolytic lesions. These lesions, formed by activated osteoclasts, cause pain, an increased susceptibility to fractures, and hypercalcemia. It has been shown that breast cancer cells communicate with osteoblasts and subsequently stimulate osteoclast activity; however, little research has focused on understanding the interaction between breast cancer cells and osteoblasts. We recently reported that conditioned medium from MDA-MB-231 breast cancer cells inhibited the differentiation of MC3T3-E1 osteoblasts through the secretion of transforming growth factor β (TGFβ). In addition, the breast cancer conditioned medium altered MC3T3-E1 morphology, the pattern of actin stress fibers, and reduced focal adhesion plaques. In the current study, we identified the mechanism used by MDA-MB-231 cells to cause these effects. When MC3T3-E1 osteoblasts were cultured with MDA-MB-231 conditioned medium preincubated with neutralizing antibodies to platelet derived growth factor (PDGF), insulin-like growth factorII (IGFII), and TGFβ, focal adhesion plaques and actin stress fiber formation were restored. These cytokines were further found to signal through PI3Kinase and Rac. In conclusion, TGFβ, PDGF, and IGFII might be good therapeutic targets for treating breast cancer-induced osteolytic lesions.
UR - http://www.scopus.com/inward/record.url?scp=26844553817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26844553817&partnerID=8YFLogxK
U2 - 10.1016/j.yexcr.2005.07.029
DO - 10.1016/j.yexcr.2005.07.029
M3 - Article
C2 - 16154565
AN - SCOPUS:26844553817
SN - 0014-4827
VL - 310
SP - 270
EP - 281
JO - Experimental Cell Research
JF - Experimental Cell Research
IS - 2
ER -